Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 8557


A review of six methods for monitoring infliximab concentrations and antibodies to infliximab

Cao F, Cao H, Cao X.

Int J Clin Pharmacol Ther. 2017 May 17. doi: 10.5414/CP202945. [Epub ahead of print]


Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.

Kelly OB, Donnell SO, Stempak JM, Steinhart AH, Silverberg MS.

Inflamm Bowel Dis. 2017 May 11. doi: 10.1097/MIB.0000000000001126. [Epub ahead of print]


Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

Liefferinckx C, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D.

Inflamm Bowel Dis. 2017 May 11. doi: 10.1097/MIB.0000000000001120. [Epub ahead of print]


Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF).

Eppinga H, Thio HB, Schreurs MWJ, Blakaj B, Tahitu RI, Konstantinov SR, Peppelenbosch MP, Fuhler GM.

PLoS One. 2017 May 9;12(5):e0176955. doi: 10.1371/journal.pone.0176955. eCollection 2017.


Potential role of nutraceutical compounds in inflammatory bowel disease.

Larussa T, Imeneo M, Luzza F.

World J Gastroenterol. 2017 Apr 14;23(14):2483-2492. doi: 10.3748/wjg.v23.i14.2483. Review.


Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies.

Wojciechowski J, Upton RN, Mould DR, Wiese MD, Foster DJR.

AAPS J. 2017 Apr 25. doi: 10.1208/s12248-017-0082-8. [Epub ahead of print]


Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.

Otake H, Matsumoto S, Mashima H.

Medicine (Baltimore). 2017 Apr;96(16):e6635. doi: 10.1097/MD.0000000000006635.


Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype.

Wang ZZ, Shi K, Peng J.

Biomed Rep. 2017 Apr;6(4):401-410. doi: 10.3892/br.2017.860. Epub 2017 Feb 17.


Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.

Sullivan E, Piercy J, Waller J, Black CM, Kachroo S.

PLoS One. 2017 Apr 14;12(4):e0175826. doi: 10.1371/journal.pone.0175826. eCollection 2017.


Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.

Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG.

Inflamm Bowel Dis. 2017 Apr 13. doi: 10.1097/MIB.0000000000001100. [Epub ahead of print]


Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study.

Banaszkiewicz A, Gawronska A, Klincewicz B, Kofla-Dłubacz A, Grzybowska-Chlebowczyk U, Toporowska-Kowalska E, Malecka I, Stryczynska-Kazubska J, Feleszko W, Lazowska-Przeorek I, Karolewska-Bochenek K, Walkowiak J, Slusarczyk J, Radzikowski A, Demkow U, Albrecht P.

Inflamm Bowel Dis. 2017 May;23(5):847-852. doi: 10.1097/MIB.0000000000001076.


Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators., Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3.


Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.

Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Osterman MT, Cheifetz AS.

Clin Gastroenterol Hepatol. 2017 Mar 29. pii: S1542-3565(17)30385-3. doi: 10.1016/j.cgh.2017.03.031. [Epub ahead of print]


Risk of cardiovascular disease in inflammatory bowel disease.

Wu P, Jia F, Zhang B, Zhang P.

Exp Ther Med. 2017 Feb;13(2):395-400. doi: 10.3892/etm.2016.3966. Epub 2016 Dec 12.


Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.

Farkona S, Soosaipillai A, Filippou P, Liaskos C, Bogdanos DP, Diamandis EP, Blasutig IM.

Clin Chem Lab Med. 2017 Mar 27. pii: /j/cclm.ahead-of-print/cclm-2016-1120/cclm-2016-1120.xml. doi: 10.1515/cclm-2016-1120. [Epub ahead of print]


Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury.

Pyzik M, Rath T, Kuo TT, Win S, Baker K, Hubbard JJ, Grenha R, Gandhi A, Krämer TD, Mezo AR, Taylor ZS, McDonnell K, Nienaber V, Andersen JT, Mizoguchi A, Blumberg L, Purohit S, Jones SD, Christianson G, Lencer WI, Sandlie I, Kaplowitz N, Roopenian DC, Blumberg RS.

Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2862-E2871. doi: 10.1073/pnas.1618291114. Epub 2017 Mar 22.


Current practice for therapeutic drug monitoring of biopharmaceuticals in inflammatory bowel disease.

Detrez I, Van Stappen T, Martín Arranz MD, Papamichael K, Gils A.

Ther Drug Monit. 2017 Mar 22. doi: 10.1097/FTD.0000000000000394. [Epub ahead of print]


Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.

Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN.

Aliment Pharmacol Ther. 2017 May;45(10):1291-1302. doi: 10.1111/apt.14030. Epub 2017 Mar 22. Review.


ANA IIF Automation: Moving towards Harmonization? Results of a Multicenter Study.

Van den Bremt S, Schouwers S, Van Blerk M, Van Hoovels L.

J Immunol Res. 2017;2017:6038137. doi: 10.1155/2017/6038137. Epub 2017 Feb 21.


The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.

Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, Stewart MJ, Beck PL, Kaplan GG, Ghosh S, Panaccione R.

Aliment Pharmacol Ther. 2017 May;45(10):1329-1338. doi: 10.1111/apt.14040. Epub 2017 Mar 20.


Supplemental Content

Loading ...
Support Center